Skip to main content

Table 1 Results of validation parameter

From: New stability indicating RP-HPLC-PDA method for determination of mifepristone in bulk and tablet formulation

Concentration of MFP (µg mL−1) Peak area
Mean ± SD (n = 6)
Amount found (μg mL−1) (n = 3) % amount found (μg mL−1) (n = 3) % RSD
Linearity studies of mifepristone
 3 348,508 ± 579.06 0.17
 6 637,116 ± 7790.85 1.22
 9 950,741 ± 3787.78 0.40
 12 1,246,160 ± 14,321.09 1.15
 15 1,571,188 ± 9559.71 0.61
 18 1,885,411 ± 12,610.39 0.67
Precision studies of mifepristone
 Intra-day precision
  6 6.00 99.98 0.11
  9 9.00 100.00 0.06
  12 11.94 99.48 0.90
 Inter-day precision
  6 6.02 100.36 0.40
  9 9.02 100.24 0.11
  12 11.94 99.54 0.57
Precision studies [repeatability]of mifepristone
 9   8.97 99.63  
 9   9.02 100.19  
 9   9.01 100.09  
 9   9.00 100.05  
 9   9.01 100.15  
 9   9.00 100.03  
Mean ± SD   9.00 ± 0.02 100.02 ± 0.20  
% RSD   0.20 0.20  
Ruggedness studies
 9 (Analyst I)    99.82 ± 0.41  
 9 Analyst II)    99.91 ± 0.27  
Parameters Tailing factor Theoretical plates % RSD  
Robustness studies of mifepristone
 Change in pH of buffer
  2.8 1.43 4046.3 0.60  
  3.0 (Optimized condition) 1.13 4097.1 0.26  
  3.2 1.21 4033.5 0.17  
 Change in mobile phase composition
  Acetonitrile/buffer (45:55) 1.35 4076.5 0.67  
  Acetonitrile/buffer (40:60; optimized condition) 1.13 4097.1 0.29  
  Acetonitrile/buffer (35: 65) 1.15 4087.6 0.24  
 Change in flow rate
  0.4 mL 1.41 4010.4 0.75  
  0.6 mL (Optimized condition) 1.13 4097.1 0.38  
  0.8 mL 1.26 4088.9 0.56  
 Change in temperature
  30 °C 1.39 4038.4 0.63  
  32 °C (Optimized condition) 1.13 4097.1 0.44  
  34 °C 1.18 4054.7 0.53  
Initial amount (μg mL−1) Excess drug added to the analyte (%) Total amount found ± SD (μg mL−1) Recovery (%) (n = 3) %RSD (n = 3)
Accuracy studies of mifepristone
 6 80 10.77 ± 1.09 99.45 1.09
 6 100 12.02 ± 0.02 100.28 0.29
 6 120 13.23 ± 0.10 100.35 1.35